Fritextsökning
Artiklar per år
Innehållstyper
-
Stamceller kan stoppa svår MS
Forskare vid Uppsala universitet visar att det är möjligt att stoppa sjukdomen multipel skleros. Genom att behandla patienter med blodstamceller har man lyckats stoppa sjukdomsförloppet.
-
Danska elitforskare belönas
Totalt 45 forskare får dela på 12 miljoner vid årets utdelning av det danska Eliteforskpriset. Ett av årets stora EliteForskpris går till en ung hjärnforskare som forskar kring Alzheimers sjukdom och hjärnskador.
-
Elekta säljer cancerteknik till Ryssland
Två ledande cancerkliniker i Moskva och Sibirien får Rysslands mest avancerade system för strålterapi.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Vitamin D is mental health aid
Vitamin D can help stave off the mental decline that can affect people in old age, a study suggests.
-
Danisco strengthens its IP team
Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Future drugs from Amaryllis
A Danish research team has discovered possibolities to extract drugs fro Amaryllis.
-
Medtech companies find new beam technique
The medtech companies Raysearch and Nucletron expand collaboration with two new solutions for radiation treatment planning.
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
-
Positive combined cancer therapy
Topotarget announces positive data with new treatment against colorectal cancer.
-
Dako appoints new CEO
The Danish cancer therapeutic company Dako has appointed a new CEO after Patrik Dahlén.
BREAKING